Actively Recruiting
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-06-26
30
Participants Needed
1
Research Sites
708 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate polypeptide sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the polypeptide vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the polypeptide vaccine immunotherapy on human cancers will firstly be evaluated.
CONDITIONS
Official Title
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with advanced cancer
- Life expectancy greater than 12 weeks
- Adequate heart, lung, liver, kidney, and blood function
- Availability of high quality vaccine for human use
- Informed consent explained, understood, and signed by patient or guardian with a copy provided
You will not qualify if you...
- Previous gene therapy treatment
- Severe viral infections such as HBV, HCV, or HIV
- Known HIV positivity
- Active infectious diseases caused by bacteria, virus, or fungi
- Other severe diseases deemed inappropriate by investigators
- Pregnant or lactating women
- Systemic steroid treatment equivalent to or above 0.5 mg prednisone/kg/day
- Any other conditions considered inappropriate by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China, 510260
Actively Recruiting
Research Team
Z
Zhenfeng Zhang, MD, PhD
CONTACT
B
Bingjia He, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here